Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents.



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:6 - 16
Updated:3/7/2019
Start Date:February 21, 2018
End Date:August 28, 2019
Contact:Teva U.S. Medical Information
Email:USMedInfo@tevapharm.com
Phone:1-888-743-9887

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets
for the reduction of motor and phonic tics associated with TS in children and adolescents 6
through 16 years of age.


Inclusion Criteria:

- Patient is 6 to 16 years of age, inclusive

- Patient weighs at least 44 pounds (20 kg)

- The patient's active tics are causing distress or impairment

- Patient is able to swallow study medication whole

- Patient is in good general health

- Women/girls of childbearing potential whose male partners are of childbearing
potential must use contraception for the duration of the study

- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

- Patient has a neurologic disorder other than Tourette syndrome (TS) that could obscure
the evaluation of tics.

- Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another
psychotic disorder.

- Patient has clinically significant depression at screening or baseline.

- Patient has a history of suicidal intent or related behaviors within 2 years of
screening.

- Patient has a history of a previous actual, interrupted, or aborted suicide attempt.

- Patient has a first-degree relative who has completed suicide.

- Patient has received comprehensive behavioral intervention for tics (CBIT) for TS or
cognitive behavioral therapy (CBT) for obsessive-compulsive disorder (OCD) within 4
weeks of screening.

- Patient has an unstable or serious medical illness at screening or baseline.

- Patient is pregnant or breastfeeding.

- Additional criteria apply, please contact the investigator for more information.
We found this trial at
18
sites
San Antonio, Texas
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
?
mi
from 91732
Ajax,
Click here to add this to my saved trials
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
1224
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Dothan, Alabama 36303
1899
mi
from 91732
Dothan, AL
Click here to add this to my saved trials
Houston, Texas 77054
1358
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Oklahoma City, Oklahoma
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
552
mi
from 91732
Orem, UT
Click here to add this to my saved trials
2184
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Petersburg, Virginia 23805
?
mi
from 91732
Petersburg, VA
Click here to add this to my saved trials
Rochester, New York
2245
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Rogers, Arkansas 72758
1354
mi
from 91732
Rogers, AR
Click here to add this to my saved trials
Sacramento, California
366
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
Saint Charles, Missouri 63304
?
mi
from 91732
Saint Charles, MO
Click here to add this to my saved trials
Saint Petersburg, Florida
2128
mi
from 91732
Saint Petersburg, FL
Click here to add this to my saved trials
San Diego, California
105
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Sun City, Arizona
330
mi
from 91732
Sun City, AZ
Click here to add this to my saved trials
Voorhees, New Jersey 08043
?
mi
from 91732
Voorhees, NJ
Click here to add this to my saved trials